While BMI is not a perfect measurement, it remains one of the most commonly used tools in clinical practice
Weight loss injections, particularly GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and dual GIP/GLP-1 agonists like tirzepatide (Zepbound, Mounjaro), have become widely prescribed for obesity management in the United States
Why three is more than one plus one plus one The combination isn't just additiveit may be synergistic: GLP-1 and GIP together enhance appetite suppression more than either alone Glucagon increases metabolic rate and fat burning The combined effect on energy balance exceeds what any single mechanism achieves Different pathways may reduce the body's ability to adapt and plateau This helps explain why Phase 2 trials showed weight loss exceeding 24%greater than approved single or dual agonists
While calories matter, the biological drivers behind appetite, satiety and energy use are powerful determinants of long term success
The combination of metformin and GLP-1 RAs, via complementary mechanisms and improved leptin sensitivity, translates into greater weight loss success response and reduced GLP-1RA-related adverse events, particularly with concurrent initiation of both agents